<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052283</url>
  </required_header>
  <id_info>
    <org_study_id>CFAbd-Score</org_study_id>
    <nct_id>NCT03052283</nct_id>
  </id_info>
  <brief_title>Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score)</brief_title>
  <acronym>CFAbd-Score</acronym>
  <official_title>Evaluation and Validation of a New Questionnaire to Identify and Quantify Abdominal Symptoms in Patients With Cystic Fibrosis Following FDA Guidelines: the CF Abd-Score (Primarily Named JenAbdomen-CF Score)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medizinische Hochschule Brandenburg Theodor Fontane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medizinische Hochschule Brandenburg Theodor Fontane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development, validation and evaluation of a new multimodal questionnaire to assess and&#xD;
      quantify the abdominal involvement in patients with the inherited life shortening multi-organ&#xD;
      disease Cystic fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Development of a multimodal questionnaire considering the FDA guidelines for patient reported&#xD;
      outcome measures (PROM)&#xD;
&#xD;
        -  Evaluation of reliability of the questionnaire by examining internal consistency and&#xD;
           construct validity&#xD;
&#xD;
        -  Evaluation of reproducibility of the questionnaire by re-testing of patients&#xD;
&#xD;
        -  Assessment of cross-generational applicability of the questionnaire by sub-scoring of&#xD;
           age groups&#xD;
&#xD;
        -  Evaluation of the responsiveness of the score by comparison with age-matched healthy&#xD;
           controls&#xD;
&#xD;
        -  Assessment of putative relationships of abdominal symptoms with faecal inflammatory&#xD;
           markers&#xD;
&#xD;
        -  Assessment of applicability of the questionnaire in other CF centers&#xD;
&#xD;
        -  Transfer the CFAbd-Score to other countries and languages&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development and evaluation of the CFAbd-Score (initially named JenAbdomen CF-Score), a CF-specific PROM following FDA recommendations</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation and validation of the CFAbd-Score based on a CF patient-reported outcome measure (PROM) that includes all relevant gastrointestinal symptoms and their impact on subjective quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings</measure>
    <time_frame>3 years</time_frame>
    <description>relating CFAbd-Scores to history, clinical- and laboratory findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients</measure>
    <time_frame>3 years</time_frame>
    <description>abdominal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of a new therapy with CFTR-modulator on abdominal symtoms, quantified with the CFAbd-Score</measure>
    <time_frame>7 years</time_frame>
    <description>Assessing the CFAbd-ScoreÂ´s sensitivity to identify and quantify changes due to effective therapeutic interventions, following FDA-guidelines for validation of a PROM</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Patients with CF</arm_group_label>
    <description>&gt;2000 in Germany, France, Italy, Spain, Denmark, Belgium, Portugal, GB, Ireland, USA, Australia, Canada, Brazil, Argentina...</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age-matched healthy controls</arm_group_label>
    <description>&gt;100 in Germany &gt;100 in each of the other participating countries</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>non-interventional</description>
    <arm_group_label>Age-matched healthy controls</arm_group_label>
    <arm_group_label>Patients with CF</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CF of all ages&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        CF cohort:&#xD;
&#xD;
        Diagnosis of CF determined by&#xD;
&#xD;
          -  a sweat chloride of &gt;60 mEq/L and/or&#xD;
&#xD;
          -  detection of 2 disease causing CFTR mutations with evidence of organ involvement.&#xD;
&#xD;
        Healthy controls:&#xD;
&#xD;
          -  Age-matched&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        CF cohort:&#xD;
&#xD;
          -  Lacking ability to cooperate of patients /their families, respectively&#xD;
&#xD;
        Healthy controls:&#xD;
&#xD;
          -  Other diseases causing abdominal symptoms (alpha 1 antitrypsin deficiency, celiac&#xD;
             disease, food allergy, gastroenteritis, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen G Mainz, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Hochschule Brandenburg (MHB), University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jochen G Mainz, Prof. MD</last_name>
    <phone>+493381411803</phone>
    <email>jochen.mainz@mhb-fontane.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anke Jaudszus, PhD</last_name>
    <phone>+4936419329510</phone>
    <email>anke.jaudszus@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Hochschule Brandenburg (MHB), University</name>
      <address>
        <city>Brandenburg an der Havel</city>
        <zip>14770</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen G Mainz, Prof. Dr.</last_name>
      <phone>+493381411803</phone>
      <email>jochen.mainz@mhb-fontane.de</email>
    </contact>
    <contact_backup>
      <last_name>Franziska Duckstein, MA</last_name>
      <email>f.duckstein@klinikum-brandenburg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Jena University Hospital</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen G Mainz, Prof. Dr.</last_name>
      <phone>+493381411803</phone>
      <email>jochen.mainz@mhb-fontane.de</email>
    </contact>
    <investigator>
      <last_name>Carlos Zagoya, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franziska Duckstein, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://link.springer.com/article/10.1007%2Fs40271-019-00361-2</url>
    <description>Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score).</description>
  </link>
  <results_reference>
    <citation>Tabori H, Arnold C, Jaudszus A, Mentzel HJ, Renz DM, Reinsch S, Lorenz M, Michl R, Gerber A, Lehmann T, Mainz JG. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS One. 2017 May 4;12(5):e0174463. doi: 10.1371/journal.pone.0174463. eCollection 2017.</citation>
    <PMID>28472055</PMID>
  </results_reference>
  <results_reference>
    <citation>Tabori H, Jaudszus A, Arnold C, Mentzel HJ, Lorenz M, Michl RK, Lehmann T, Renz DM, Mainz JG. Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients. Sci Rep. 2017 Dec 12;7(1):17465. doi: 10.1038/s41598-017-17302-4.</citation>
    <PMID>29234058</PMID>
  </results_reference>
  <results_reference>
    <citation>Jaudszus A, Zeman E, Jans T, Pfeifer E, Tabori H, Arnold C, Michl RK, Lorenz M, Beiersdorf N, Mainz JG. Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score). Patient. 2019 Aug;12(4):419-428. doi: 10.1007/s40271-019-00361-2.</citation>
    <PMID>30887269</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medizinische Hochschule Brandenburg Theodor Fontane</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Jochen G. Mainz</investigator_full_name>
    <investigator_title>Director of the Cystic Fibrosis-Center</investigator_title>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Abdomen</keyword>
  <keyword>Pancreas</keyword>
  <keyword>Liver</keyword>
  <keyword>Gut</keyword>
  <keyword>Symptom Score</keyword>
  <keyword>Patient reported outcome measure (PROM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

